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Background: The wearing-off phenomenon in patients with Parkinson’s disease (PD) is a complication of prolonged
levodopa usage. During this phenomenon, motor symptoms such as rigidity and freezing re-emerge. This is often
accompanied by non-motor symptoms, including anxiety, the so-called wearing-off related anxiety (WRA). Current
treatment options are limited and typically focus on either the physical or mental aspects of wearing-off. An integrated
approach seems warranted in order to optimally address the complex reciprocal interactions between these aspects.
Also, because wearing-off is eventually inescapable, treatment needs to focus on coping, acceptance, and self-efficacy.
We therefore developed an integrated body awareness intervention, combining principles from physical therapy with
acceptance and commitment therapy to teach patients to deal with WRA. This study will investigate whether this new
intervention, named BEWARE, is more effective than treatment as usual in increasing self-efficacy.
Methods/Design: This is a single-blinded randomized controlled trial in 36 PD patients who experience WRA. Subjects
will be recruited from the outpatient clinic for movement disorders of the VU University Medical Center. After providing
written informed consent, patients will be randomly assigned to an experimental (BEWARE) or treatment-as-usual
(physical therapy) group. Clinical assessments will be performed prior to the intervention, directly after the 6-week
intervention period, and at 3-month naturalistic follow-up by a blinded investigator not involved in the study. The
primary outcome measure is self-efficacy, and secondary outcomes focus on mobility, daily functioning, anxiety, and
quality of life.
Discussion: Because wearing-off is an inevitable consequence of levodopa therapy and current treatment options are
insufficient, a multidisciplinary intervention that addresses both physical and mental aspects of wearing-off in PD may
foster additional benefits for treating WRA in PD patients over mono-disciplinary care alone.
Trial registration: ClinicalTrials.gov identifier: NCT02054845. Date of registration: 30 January 2014.
Keywords: Parkinson’s disease, Wearing-off, Anxiety, Body awareness, Randomized controlled trial, Self-efficacy* Correspondence: oa.vandenheuvel@vumc.nl
1Department of Psychiatry, VU University Medical Center, PO Box 7057, 1007
MB Amsterdam, The Netherlands
2Department of Anatomy & Neurosciences, VU University Medical Center,
Van der Boechorststraat 7, 1081 BT Amsterdam, The Netherlands
Full list of author information is available at the end of the article
© 2015 Ghielen et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ghielen et al. Trials  (2015) 16:283 Page 2 of 7Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive disorder of the central nervous system and has a
prevalence of 1.6 % among people who are at least 65
years old [1]. The neurobiological hallmark of PD is a loss
of dopaminergic cells, causing the typical motor symp-
toms such as tremor, rigidity, slowness of movement, pos-
tural instability, and freezing. Non-motor symptoms, such
as autonomic failure, fatigue, depression, and anxiety are
also prevalent and this is likely due to an additional
involvement of non-dopaminergic systems [2].
To supplement the shortage of dopamine, levodopa
treatment is currently the most applied and effective
symptomatic treatment [3]. When the dopamine replace-
ment therapy (DRT) takes effect and symptoms become
less prominent, the patient is in the ‘on’ state. In contrast,
the state in which the patient is in need of a new dose of
dopamine and experiences intensified PD symptoms is
referred to as the ‘off ’ state. A re-emergence of PD symp-
toms, shifting from an ‘on’ state to an ‘off ’ state, is called
wearing-off. This typically occurs prior to the next sched-
uled dose of dopaminergic therapy taking effect [4] and is
related to longer disease duration [5].
Motor and non-motor symptoms have reciprocal in-
fluences [6]. About 75 % of patients with motor fluctua-
tions, including wearing-off, experience mood or anxiety
fluctuations or both in parallel [7]. This wearing-off re-
lated anxiety (WRA) is characterized not only by sub-
jective feelings of anxiety but also by physical
complaints, such as sweating, abdominal distress, and
shortness of breath. Rutten et al. [8], by performing a
factor analysis on the Beck Anxiety Inventory (BAI),
showed that anxiety symptoms in PD show significant
overlap with both autonomic and motor symptoms. This
finding demonstrates that physical and mental symp-
toms are intertwined in PD.
The physical symptoms accompanying WRA are often
incongruent with the actual severity and physical impact
of motor symptoms of wearing-off, suggesting an
increased sensitivity and reactivity to the occurrence of
wearing-off symptoms and heightened body awareness in
these patients. Body awareness involves a focus on and
awareness of internal bodily sensations [9]. An abnormal
increase in body awareness can be maladaptive [9] and is,
in general, also related to anxiety disorders [10–14].
The anxiety symptoms experienced by patients with PD
are often responsive to dopaminergic medication [15].
Therefore, the first therapeutic approach for treating
WRA is to optimize the DRT [16]. As the disease pro-
gresses, increasing dopaminergic medication (both fre-
quency and dosage) becomes insufficient and complicated
because of the increased occurrence of dyskinesias [17].
Also, random fluctuations appear to be more difficult to
treat with pharmacotherapeutic approaches because theyare unpredictable and not directly related to a lower level
of dopamine [17].
Non-pharmaceutical approaches include exercise pro-
grams and physical therapy. These have been shown to
improve motor problems, daily functioning, and quality
of life in patients with PD [18–21]. Though effective for
improving mobility-related problems, current physical
rehabilitation approaches typically do not offer tools to
address the non-motor symptoms of wearing-off.
Cognitive behavior therapy (CBT), mindfulness, and
acceptance and commitment therapies (ACTs) have
proven to be effective in reducing anxiety symptoms and
avoidance behavior in patients with anxiety disorders,
also enhancing quality of life [22, 23]. Therefore, classic
tools from CBT and ACT might be useful in the treat-
ment of the debilitating effects of WRA. A reduction of
anxiety symptoms in patients with PD is observed in
most of the CBT studies [24–26]. However, based on
clinical experience, efficacy of classic CBT is limited in
PD care because the cognitive methods are suboptimal
in addressing the interaction between non-motor and
motor symptoms during wearing-off. Moreover, the clas-
sic approaches aim to reduce the symptoms, whereas
the inevitability of motor and non-motor fluctuations in
PD demands the ability to maintain physical and mental
balance despite the presence of those fluctuations. This
is of great importance mainly in the more advanced
stages of PD, in which symptom management is more
challenging [3]. Therefore, interventions need to focus
on independence and self-efficacy more than on redu-
cing symptoms.
To address both the physical and the mental aspects of
PD, Wahbeh et al. [27] reviewed mind-body interventions
in the treatment of PD and showed that participating in
tai chi classes improved the patients’ physical condition.
Landsman-Dijkstra et al. [28] tested a highly structured
and standardized 3-day body awareness program in 14
participants who had chronic non-specific psychosomatic
symptoms. Increases of body awareness, self-efficacy, and
quality of life were found after the intervention. However,
the researchers did not implement a control group in this
study.
Mindfulness-based therapies have proven to be effective
in many patient groups, such as patients with chronic
pain, anxiety, and depressive disorders, by improving psy-
chological functions and reducing pain and stress [29, 30],
although the mean effect size was small (0.42) [30]. In
addition, Åkerblom et al. [31] showed that pain-related
acceptance is the strongest mediator in CBT treatment in
patients with chronic pain. The authors conclude that
targeting of acceptance in treatment may lead to further
improvements in outcome measures. It has been shown
that CBT is effective in PD patients even after a follow-up
period on anxiety and coping measures [32]. Because PD
Fig. 1 Study flow chart. BEWARE body awareness training,
PD Parkinson’s disease, TAU treatment as usual
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and mental symptoms (motor and non-motor symptoms),
combining mindfulness-based therapy with physical re-
habilitation might be of potential benefit for PD patients
with WRA.
BEWARE is an integrated body awareness interven-
tion, combined with ACT, in which mindfulness training
is incorporated with physical therapy. We will test the
effectiveness of this intervention—compared with treat-
ment as usual (TAU)—in terms of self-efficacy in PD pa-
tients with WRA. We hypothesize that the BEWARE
intervention will be more effective than physical therapy
alone (TAU) in improving self-efficacy.
Methods/Design
Study design
This will be a single-blind randomized controlled trial.
Thirty-six PD patients who experience WRA will be ran-
domly allocated either to the BEWARE training group
(n = 18, three groups of six patients) or to a control
group receiving physical group therapy, which is a usual
form of treatment for wearing-off in patients with PD at
the VU University Medical Center (n = 18, three groups
of six patients). Block randomization is done by using
concealed opaque envelopes. All participants are asked
to maintain the regular medication schedule during the
6-week intervention. Assessments are conducted prior
to the intervention and at 6 weeks directly after the
intervention. Also, long-term effects will be assessed at
18 weeks of follow-up (from post-enrolment). The
assessments will be performed by a blinded investigator
who is not involved in the intervention or randomization.
Figure 1 demonstrates the study design according to the
CONSORT (Consolidated Standards of Reporting Trials)
statement [33].
Patient recruitment
The patients will be recruited from the outpatient clinic
of the VU University Medical Center. The neurologists
and psychiatrist will be asked to approach PD patients
who, in their view, experience WRA. In addition, an an-
nouncement will be placed on the website of the Dutch
Parkinson patient association (Parkinson Vereniging)
and in their magazine. Inclusion and exclusion criteria
are listed below.
Patient inclusion criteria
1. Given a diagnosis of idiopathic PD according to the
UK PD Brain Bank criteria [34].
2. Experiencing wearing-off symptoms or response
fluctuations (or both), as measured with the
Wearing-Off Questionnaire 19 [35]. A patient is
considered to be experiencing wearing-off if he orshe indicates at least one symptom that improves
after taking a next medication dose.
3. Presence of clinically relevant anxiety, defined as a
BAI score of more than 26 [36].Patient exclusion criteria
1. Other neurological, orthopaedic, or
cardiopulmonary problems that in the view of the
researchers may interfere with participation.
2. Cognitive impairment defined as a Mini Mental
State Examination (MMSE) score of less than 24.
3. Insufficient motivation for participation.Intervention
Two treatment conditions are investigated in this study:
the experimental condition (BEWARE) and the TAU
(physical therapy). Both interventions consist of 12
sessions, each 1 hour long, two times per week for
6 weeks. All treatment sessions occur at the same time
of day on the same two days of the week (Monday and
Thursday) throughout the study. The treatment groups
consist of six patients, in both conditions.
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The experimental intervention is delivered by profes-
sionals from the fields of psychology, physical therapy,
and psychiatry. The BEWARE training is based mainly
on the principles of ACT [37]. The goals of this training
are to acquire and apply adequate coping strategies with
wearing-off and live a valuable life despite the presence
of wearing-off symptoms.
In the first therapy session, psycho-education about
PD and wearing-off is discussed by the psychiatrist. In
the following sessions, the psychologist explains and
provides training in the concepts of body awareness,
cognitive defusion, and valued living and prepares the
patients for the imaginary exposure. Body awareness is
achieved by using attentional exercises. Cognitive defusion
techniques attempt to change the way the patient interacts
or relates to thoughts, by observing one’s thoughts in a
non-judgemental manner. In ACT, valued living is
achieved by choosing personal life directions while under-
mining choices based on avoidance or social compliance.
Imaginary exposure, in ACT therapy known as FEEL
(Feeling Experiences Enriches Living) exercises [37], is
applied during sessions 6 to 12. During the imaginary
exposure, patients are asked to imagine a real-life situation
that easily triggers wearing-off. The patients practice with
experiencing and daring to allow the feelings that are trig-
gered by the ‘off ’ during this imaginary exposure.
Throughout these sessions, the ‘off ’ situations become
more challenging and patients are encouraged to gradually
take part in activities that they previously avoided because
of the (anticipation of) wearing-off.
The psychological exercises are alternated by physical
exercises that are performed by the physical therapist.
These exercises include strategies for starting and per-
forming complex movements with risk of falling, such as
sitting down and rising from a chair, called transfers. Also,
standing, initiation of walking, and walking in complex or
stressful situations are addressed. Lastly, moving to rhyth-
mic music helps the patients to relieve stress after the im-
aginary exposure. These aspects teach the patient to be
able to cope with wearing-off situations. To generalize the
intended effect, the patients are given homework assign-
ments, such as body awareness exercises and planning
value-based committed actions in daily life.
Control condition: treatment as usual
The patients in the control group receive TAU based on
the current KNGF (Royal Dutch Society for Physical
Therapy) guidelines for physical therapy in patients with
PD [38]. The group treatment contains exercises for bal-
ance, walking, posture, reaching and grasping, strength,
flexibility, relaxation, and physical condition. As in the
experimental condition, patients are taught strategies on
how to make transfers.Outcome measures
Primary outcome measure
The primary outcome measure is self-efficacy, assessed
with the 10-item General Self-Efficacy Scale (GSES) [39].
Self-efficacy is defined as the extent or strength of one’s
belief in one’s own ability to complete tasks and reach
goals (in other words, a person’s belief in his or her abil-
ity to succeed in a particular situation) [40]. In this ques-
tionnaire, patients are asked to rate specific statements
on a scale from 1 to 4 (1 = not at all true, 2 = hardly
true, 3 = moderately true, and 4 = exactly true). The
GSES has proven to be a valuable and reliable outcome
measure in patients with PD [41].
Secondary outcome measures
1. The Parkinson’s Disease Questionnaire-39 (PDQ-39)
This questionnaire is a measure of quality of life
adapted for people with PD [42]. It consists of 39 state-
ments that cover eight domains associated with health,
such as mobility and emotionality, that can be influ-
enced by PD. Patients can reply by ticking the relevant
answer that indicates whether they experienced prob-
lems during the past month (five boxes from ‘never’ to
‘always’). The PDQ-39 is a valid and reliable instrument
for patients with PD [42, 43].
2. The Wearing-off Questionnaire 19 (WOQ-19)
In this 19-item questionnaire [35], patients with PD
indicate which symptoms they experience and whether
these symptoms improve after administration of PD
medication.
3. Beck Anxiety Inventory (BAI)
This self-report questionnaire consists of 21 common
symptoms of anxiety [36]. Patients indicate how much
they have been bothered by these symptoms during the
past week, including today.
4. Beck Depression Inventory
This 21-item self-report questionnaire measures
whether patients experience depressive symptoms [44].
Patients indicate the statements that are most applicable
to their own situation during the past week, including
today.
5. 10-Meter Walk Test (10MWT)
To measure comfortable walking speed, the patients
are asked to walk 10 metres, which are characterized by
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measures the time needed to cover this distance.
6. Timed One-Leg Stance Test (OLST)
This test measures balance by asking the patients to
stand on one leg without help [46]. The number of
seconds that the patients maintain their balance is noted;
the maximum is 60 seconds.
7. The Nottingham Extended Activities of Daily Living
(NEADL) index
This 22-item self-report questionnaire covers four
aspects of daily living: mobility, activities in the kitchen,
domestic tasks, and leisure activities [47]. Patients indi-
cate whether they independently performed activities
during the past weeks.
8. Freezing of Gait (FOG) questionnaire
This six-item questionnaire is used to identify current
problems with walking and symptoms of freezing [48].
For each item, patients indicate which of the five state-
ments is most applicable.
9. Visual Analogue Scales (VASs)
Before and after each therapy session, patients indicate
how they are feeling at the actual moment by using 10
VASs. Patients put a cross on a line of 10 cm with
extreme feelings at the edges (for example, ‘relaxed’ or
‘tense’, ‘in control’ or ‘out of control’, and ‘happy’ or ‘sad’).
Patient researchers
Because the experimental treatment is a new approach,
the opinion and experiences of the participating patients
are considered very important. Therefore, two patient
researchers of the Dutch Parkinson patient association
(Parkinson Vereniging) contribute to the study by
anonymously documenting the patients’ expectations and
evaluation points for qualitative analysis. Prior to and dir-
ectly after the intervention period, a semi-structured
group interview takes place in which the patients are
asked questions related to the study and can share their
experiences and suggestions for adaptations in future
studies or in the implementation phase. This interview is
with the patients (both participants and researchers) only.
Statistical analysis
Calculation of sample size
We expect that, compared with the TAU group, the
experimental group will show a 10 % larger improve-
ment on the GSES after treatment. Nieuwboer et al. [49]investigated a 3-week physical home training program
and showed that physical measures improved with 4.2–
5.5 % compared with 3 weeks of no therapy. Because we
expect the effects of the combination of physical therapy
and ACT in the BEWARE intervention to be stronger
and the intervention period to be longer and more
intensive, we hypothesize a larger difference in our
primary outcome measure. Considering this study and
data on the GSES in other chronic diseases [50], we
expect to detect a 10 % larger reduction in GSES score
from 32 to 28.8 and an overall standard deviation of 3.3.
A minimum of 16 patients is required per arm of the
trial. With that, including a dropout of 10 %, we estimate
that 36 patients with PD (18 per arm) are needed to
achieve a sufficient statistical power of 80 % with two-
tailed significance level set at a P value of less than 0.05.
Data analysis
To promote data quality, double data entry will be used.
Multiple imputation will be applied on missing data.
Analysis of variance with repeated measures will be used
for normally distributed outcomes at interval and ratio
level. Friedman’s non-parametric repeated measures test
will be applied for outcomes with non-interval or ratio
scale level or for non-normally distributed variables.
Factors in the analysis will be group (two levels: control
and experimental) and time (three levels: baseline,
assessment at week 6 (directly post-treatment), and
assessment week 18 (3-month follow-up)).
Ethical considerations
Prior to study participation, written informed consent
will be obtained from the patients. This study was
approved by the ethics committee of the VU University
Medical Center (Medisch Ethische Toetsingscommissie
(METc), study number 13.421).
Data monitoring
The data and safety monitoring board will guard the
quality and safety during this study in accordance with
the Good Clinical Practice guidelines.
Discussion (expected results)
Wearing-off is an inevitable and disabling consequence
of long-term DRT in patients with PD, and WRA is a
concept characterized by a complex reciprocal inter-
action of motor and non-motor symptoms. The general
neglect of these complex interactions in the TAU leaves
a gap for treatment innovation. BEWARE is a promising
therapy for WRA in PD because it specifically focuses
on the interaction between physical and mental symp-
toms. The specific and unique combination of elements
of the therapy aims to increase self-efficacy by strength-
ening one’s own belief to adequately cope with the
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of anxiety rather than reduce or eliminate symptoms.
Because the development of wearing-off is associated
with long-term treatment of PD with DRT as well as
with an early onset of disease, longer disease duration,
and higher doses of levodopa [5, 17, 51], we will inad-
vertently include patients who are in a more advanced
stage of the disease. Therefore, we must pay specific
attention to the potential additional difficulties with
patient compliance regarding the amount of effort and
commitment we demand from the patients during the
twice-weekly intervention.
Considering previous research in combination with
our own experience based on a small open pilot study in
four patients with PD (results not published), we expect
to see a significantly bigger improvement in self-efficacy
in the BEWARE condition as compared with the TAU
condition. In the pilot study, we observed a decrease in
BAI total score in the participating patients. In addition,
they reported very positive subjective effects of the inter-
vention. In particular, the group aspect and the holistic
approach to address WRA were highly appreciated.
Patients stated that they were better able to cope with
wearing-off after the intervention period. Considering
these first experiences, we believe that BEWARE has the
potential to be implemented into health-care practices
once its value has been established by using proper
testing with high methodological standards.
Because the wearing-off phenomenon is eventually in-
escapable, this study is of great interest not only from a
patient and caregiver perspective but also from a health-
care system perspective. Group therapy may lower
health-care costs compared with individual treatment
because of a reduced therapist/patient ratio, and this
treatment may allow patients to function longer and in a
more independent way in their own home environment.
Trial status
Data collection started in January 2014. The expected
completion date is August 2015.
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